南非季节性流感疫苗接种规划的成本效果分析
该研究采用WHO的CETSIV决策树模型,从公共医疗提供者和社会视角评估南非2018年季节性流感疫苗接种策略的成本效果。结果显示,除6-59月龄儿童外,该规划对所有脆弱人群均具成本效果;概率敏感性分析中,孕妇、HIV/AIDS患者、有基础疾病者及≥65岁人群在超过80%的模拟中具成本效果。
要点
- 南非常规就诊时接种三价灭活流感疫苗对多数脆弱人群具成本效果。
- 6-59月龄儿童ICER约7500美元/QALY,超过3400美元/QALY阈值。
- 成本效果结论对模型输入变化稳健,但对流感疾病负担估计最敏感。
核心结论
- 南非在常规就诊时机会性接种流感疫苗对脆弱人群具成本效果。
- 除6-59月龄儿童外,其余脆弱人群的ICER均低于3400美元/QALY阈值。
研究设计与样本
- 采用WHO的CETSIV决策树模型,评估2018年南非季节性流感疫苗接种活动。
- 分析视角为公共医疗提供者和社会视角,比较接种与不接种的成本和效益。
- 脆弱人群包括≥65岁者、孕妇、HIV/AIDS患者、任何年龄有基础疾病者及6-59月龄儿童。
主要发现
- HIV/AIDS患者和其他基础疾病者避免的临床事件数最多。
- 概率敏感性分析中,孕妇、HIV/AIDS患者、有基础疾病者及≥65岁者在超过80%的模拟中具成本效果。
- 结果对多数模型输入变化稳健,但对流感相关疾病负担估计的不确定性最敏感。
关键数值与推荐
- 成本效果阈值为每质量调整生命年3400美元。
- 6-59月龄儿童的ICER超过成本效果阈值。
临床怎么用
- 可优先维持或扩大对孕妇、HIV/AIDS患者、有基础疾病者及≥65岁人群的流感疫苗接种。
- 针对6-59月龄儿童的接种策略需进一步评估成本效果以指导决策。
局限性
- 结果对流感相关疾病负担估计的不确定性最敏感。
- 研究未包含预算影响分析,作者建议未来扩展规划时补充。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Seasonal influenza imposes a significant health and economic burden in South Africa, particularly in populations vulnerable to severe consequences of influenza. This study assesses the cost-effectiveness of South Africa's seasonal influenza vaccination strategy, which involves vaccinating vulnerable populations with trivalent inactivated influenza vaccine (TIV) during routine facility visits. Vulnerable populations included in our analysis are persons aged ≥ 65 years; pregnant women; persons living with HIV/AIDS (PLWHA), persons of any age with underlying medical conditions (UMC) and children aged 6-59 months. METHOD: We employed the World Health Organisation's (WHO) Cost Effectiveness Tool for Seasonal Influenza Vaccination (CETSIV), a decision tree model, to evaluate the 2018 seasonal influenza vaccination campaign from a public healthcare provider and societal perspective. CETSIV was populated with existing country-specific demographic, epidemiologic and coverage data to estimate incremental cost-effectiveness ratios (ICERs) by comparing costs and benefits of the influenza vaccination programme to no vaccination. RESULTS: The highest number of clinical events (influenza cases, outpatient visits, hospitalisation and deaths) were averted in PLWHA and persons with other UMCs. Using a cost-effectiveness threshold of US$ 3400 per quality-adjusted life year (QALY), our findings suggest that the vaccination programme is cost-effective for all vulnerable populations except for children aged 6-59 months. ICERs ranged from ~US$ 1 750 /QALY in PLWHA to ~US$ 7500/QALY in children. In probabilistic sensitivity analyses, the vaccination programme was cost-effective in pregnant women, PLWHA, persons with UMCs and persons aged ≥65 years in >80% of simulations. These findings were robust to changes in many model inputs but were most sensitive to uncertainty in estimates of influenza-associated illness burden. CONCLUSION: South Africa's seasonal influenza vaccination strategy of opportunistically targeting vulnerable populations during routine visits is cost-effective. A budget impact analysis will be useful for supporting future expansions of the programme.
引用
- Edoka I, Kohli-Lynch C, Fraser H, et al. A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme. Vaccine. 2020. PMID: 33272702. doi:10.1016/j.vaccine.2020.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。